Dicot Pharma

0.626

SEK

+2.12 %

Less than 1K followers

DICOT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization.

Market cap

1.26B SEK

Turnover

5.85M SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Financial calendar

11/8

2025

Interim report Q2'25

22/10

2025

Interim report Q3'25

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release5/28/2025, 6:40 AM

Dicot Pharma AB: Dicot Pharma's new findings on mechanism of action: "affects the nerves controlling penile erection"

Regulatory press release5/28/2025, 6:40 AM

Dicot Pharma AB: Dicot Pharma om nya fynd inom verkningsmekanismen: "påverkar nerverna som kontrollerar erektionen"

Regulatory press release5/6/2025, 4:54 PM

Dicot Pharma AB: Report from the Annual General Meeting of Dicot Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release5/6/2025, 4:54 PM

Dicot Pharma AB: Kommuniké från Dicot Pharmas årsstämma

Regulatory press release4/29/2025, 6:15 AM

Dicot Pharma AB: Dicot Pharma presents interim report Q1 2025

Regulatory press release4/29/2025, 6:15 AM

Dicot Pharma AB: Dicot Pharma presenterar delårsrapport Q1 2025

Regulatory press release4/11/2025, 8:41 AM

Dicot Pharma AB: Dicot Pharma publicerar årsredovisningen 2024

Regulatory press release4/3/2025, 7:00 AM

Dicot Pharma AB: Summon to Annual General Meeting in Dicot Pharma May 6 at 17.00

Regulatory press release4/3/2025, 7:00 AM

Dicot Pharma AB: Kallelse till årsstämma i Dicot Pharma 6 maj kl 17

Regulatory press release4/2/2025, 6:30 AM

Dicot Pharma AB: Dicot Pharmas TO 6 nyttjades till 96% och tillför bolaget 43,8 miljoner kronor

Regulatory press release4/2/2025, 6:30 AM

Dicot Pharma AB: Dicot Pharma's TO 6 subscribed at 96% and provides the company SEK 43.8 million

Regulatory press release3/26/2025, 12:43 PM

Dicot Pharma AB: Sista dag för handel med teckningsoptioner TO 6 i Dicot Pharma imorgon 27 mars

Regulatory press release3/26/2025, 12:43 PM

Dicot Pharma AB: Last day of trading in Dicot Pharma TO 6 warrants tomorrow, March 27

Press release3/17/2025, 2:34 PM

Dicot Pharma AB: Dicot Pharma bjuder in till frågestund om TO 6

Press release3/17/2025, 2:34 PM

Dicot Pharma AB: Dicot Pharma invites to a Q&A session on TO 6

Regulatory press release3/17/2025, 7:15 AM

Dicot Pharma AB: Nyttjandeperioden för teckningsoptioner TO 6 i Dicot Pharma inleds idag

Regulatory press release3/17/2025, 7:15 AM

Dicot Pharma AB: Exercise Period for Warrants TO6 in Dicot Pharma Begins Today

Regulatory press release3/13/2025, 10:50 AM

Dicot Pharma AB: Letters of Intent from Major Shareholders, Board, and Management to Subscribe for SEK 11 million in Dicot Pharma's TO 6, Running Until March 31, 2025

Regulatory press release3/13/2025, 10:50 AM

Dicot Pharma AB: Avsiktsförklaringar från större ägare, styrelse och ledning att teckna för 11 miljoner kronor i Dicot Pharmas TO 6 som pågår till 31 mars 2025

Regulatory press release3/11/2025, 7:30 AM

Dicot Pharma AB: Subscription Price SEK 0.38 for Warrants TO 6 in Dicot Pharma Determined; corresponding to SEK 0.19 per share

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.